Neutropenia  >>  Gazyva (obinutuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens

Ongoing
2
70
Europe
obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro
HOVON Foundation, Dutch Cancer Society, Roche
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
GIBB, NCT02320487: A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Completed
2
102
US
Bendamustine, Treanda, Levact, Obinutuzumab, GA101, Gazyva™, RO5072759
Genentech, Inc.
Chronic Lymphocytic Leukemia
11/16
02/19
NCT02071225 / 2013-003388-79: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Completed
2
72
Europe
bendamustine, obinutuzumab, RO5072759
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
11/18
11/18
NOBILITY, NCT02550652 / 2015-002022-39: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Checkmark Efficacy and safety data from NOBILITY trial for lupus nephritis
Nov 2020 - Nov 2020: Efficacy and safety data from NOBILITY trial for lupus nephritis
Checkmark Safety and efficacy data from trial for lupus nephritis at ASN/ACR 2019
Nov 2019 - Nov 2019: Safety and efficacy data from trial for lupus nephritis at ASN/ACR 2019
Checkmark Safety and efficacy data from NOBILITY trial in lupus nephritis
More
Completed
2
126
Europe, US, RoW
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Methylprednisolone, Prednisone
Hoffmann-La Roche
Lupus Nephritis
01/19
08/23
NCT02983617 / 2016-002768-15: Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Completed
2
36
Europe
Tirabrutinib, GS-4059, ONO-4059, Entospletinib, GS-9973, Obinutuzumab, Gazyvaro®, Gazyva®, GA101
Gilead Sciences, German CLL Study Group
Chronic Lymphocytic Leukemia
02/19
10/20
NCT02968563 / 2015-003909-42: Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
2
35
Europe
Tirabrutinib, GS-4059, Idelalisib, Zydelig®, GS-1101, CAL-101, Obinutuzumab, Gazyvaro®, Gazyva®, GA101
Gilead Sciences, German CLL Study Group
Chronic Lymphocytic Leukemia
06/19
01/21
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio.

Not yet recruiting
2
78
Europe
Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
OLYMP-1, NCT03322865 / 2017-003149-56: Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting
2
56
Europe
Obinutuzumab, GA101
Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG
Marginal Zone Lymphoma
06/24
11/28
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Recruiting
2
230
US
Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199
Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
02/25
02/25
CAVALLI, NCT02055820 / 2013-003749-40: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Checkmark CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in front-line DLBCL at ASH 2016
Dec 2016 - Dec 2016: CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in front-line DLBCL at ASH 2016
Checkmark CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in first-line aggressive NHL at ASCO 2016
Jun 2016 - Jun 2016: CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in first-line aggressive NHL at ASCO 2016
Completed
1/2
267
Europe, Canada, US, RoW
Venetoclax, GDC-0199, ABT-199, Cyclophosphamide, Obinutuzumab, Rituximab, MabThera/Rituxan, Doxorubicin, Vincristine, Prednisone
Hoffmann-La Roche, AbbVie
Lymphoma, Non-Hodgkin
06/17
06/19
NCT03135262 / 2016-002480-34: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
1/2
29
Europe, US, RoW
Idasanutlin, Obinutuzumab, Venetoclax, Rituximab
Hoffmann-La Roche
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
04/20
04/20
NCT03010358: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Completed
1/2
24
US
Entospletinib, ENTO, GS 9973, GS-9973, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pharmacological Study
Alexey Danilov, MD, Gilead Sciences, Oregon Health and Science University
Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
04/21
04/21

Download Options